179 related articles for article (PubMed ID: 24726733)
21. High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer.
Lipponen P; Aaltomaa S; Tammi R; Tammi M; Agren U; Kosma VM
Eur J Cancer; 2001 May; 37(7):849-56. PubMed ID: 11313172
[TBL] [Abstract][Full Text] [Related]
22. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells.
Silva MM; Matheus WE; Garcia PV; Stopiglia RM; Billis A; Ferreira U; Fávaro WJ
Int Braz J Urol; 2015; 41(5):849-58. PubMed ID: 26689510
[TBL] [Abstract][Full Text] [Related]
23. Periostin is up-regulated in high grade and high stage prostate cancer.
Tischler V; Fritzsche FR; Wild PJ; Stephan C; Seifert HH; Riener MO; Hermanns T; Mortezavi A; Gerhardt J; Schraml P; Jung K; Moch H; Soltermann A; Kristiansen G
BMC Cancer; 2010 Jun; 10():273. PubMed ID: 20534149
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of the Gleason score in prostate cancer.
Egevad L; Granfors T; Karlberg L; Bergh A; Stattin P
BJU Int; 2002 Apr; 89(6):538-42. PubMed ID: 11942960
[TBL] [Abstract][Full Text] [Related]
28. Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers.
Yao M; Yu E; Staggs V; Fan F; Cheng N
Mod Pathol; 2016 Aug; 29(8):810-23. PubMed ID: 27125354
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
30. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
31. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
32. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
33. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
Hermani A; Hess J; De Servi B; Medunjanin S; Grobholz R; Trojan L; Angel P; Mayer D
Clin Cancer Res; 2005 Jul; 11(14):5146-52. PubMed ID: 16033829
[TBL] [Abstract][Full Text] [Related]
34. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
35. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
36. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.
Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B
Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359
[TBL] [Abstract][Full Text] [Related]
37. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
[TBL] [Abstract][Full Text] [Related]
38. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
39. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
40. A systems-based modelling approach using transurethral resection of the prostate (TURP) specimens yielded incremental prognostic significance to Gleason when predicting long-term outcome in men with localized prostate cancer.
Donovan MJ; Khan FM; Bayer-Zubek V; Powell D; Costa J; Cordon-Cardo C
BJU Int; 2012 Jan; 109(2):207-13. PubMed ID: 21733075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
